Hca Healthcare Inc Stock Price, News & Analysis

HCA Healthcare (NYSE:HCA) has announced its upcoming second quarter 2025 earnings conference call. The call will take place on Friday, July 25, 2025, at 10:00 AM Eastern Time (9:00 AM Central).

Investors and interested parties can access the live audio webcast through the company's investor relations website. For those unable to attend the live event, an archived version of the webcast will be made available on the same platform.

HCA Healthcare (NYSE:HCA) announced that its Foundation will provide a $1 million grant to Educate Texas through its Healthier Tomorrow Fund. This grant builds upon a previous $1.35 million grant from 2022 and aims to expand healthcare career pathways in P-TECH schools.

The initial collaboration has already increased healthcare career programs from 20 to 104 schools, enrolling nearly 10,000 high school students. The P-TECH model enables students to earn both a high school diploma and a no-cost, two-year post-secondary degree. The new funding will support program expansion across North Texas, Austin, San Antonio, and the Houston Gulf Coast region.

The HCA Healthcare Foundation's Healthier Tomorrow Fund has provided over $21 million in grants nationwide, demonstrating HCA's commitment to strengthening the healthcare workforce through various educational initiatives.

HCA Healthcare (NYSE:HCA) has announced a $5 million donation to Belmont University's Thomas F. Frist, Jr. College of Medicine to support the Belmont Collaborative for Health Systems Innovation. The gift will be split between creating the HCA Healthcare Health Systems Science Endowed Chair ($2.5M) and programmatic support for the Health Systems Science department ($2.5M). The endowed chair will be matched through the Johnson Academic Challenge program. The college welcomed its first class of 50 medical students in July 2024, who will complete clinical rotations at HCA Healthcare's TriStar Health facilities. The partnership builds on historical connections between the institutions, including the medical college's namesake Dr. Thomas F. Frist, Jr., who co-founded HCA Healthcare in 1968.

HCA Healthcare (NYSE: HCA) has announced its participation in the Bank of America 2025 Healthcare Conference. The presentation is scheduled for May 13, 2025, at 9:20 AM PT. Investors and interested parties can access the live audio webcast and presentation materials through HCA Healthcare's Investor Relations website at www.hcahealthcare.com. The company notes that dates and times may be subject to change and recommends checking the conference schedule or company website for the most current information.

HCA Healthcare (NYSE: HCA) reported strong Q1 2025 financial results with revenues reaching $18.321 billion, up from $17.339 billion in Q1 2024. Net income grew to $1.610 billion ($6.45 per diluted share) compared to $1.591 billion ($5.93 per diluted share) in Q1 2024.

Key operational metrics showed positive trends with same facility admissions increasing 2.6% and equivalent admissions up 2.8%. Emergency room visits rose 4.0%, while inpatient surgeries increased 0.2%. However, outpatient surgeries declined 2.1%. The company's Adjusted EBITDA reached $3.733 billion, up from $3.353 billion year-over-year.

During Q1 2025, HCA repurchased 7.762 million shares for $2.506 billion and declared a quarterly dividend of $0.72 per share. The company maintained its 2025 guidance, citing stable operating conditions and growing healthcare demand.

Two major clinical trials across 92 HCA Healthcare hospitals have demonstrated a breakthrough in improving antibiotic selection for hospitalized patients with abdominal or skin/soft tissue infections. The studies, involving over 316,000 patients, showed that computerized alerts helping clinicians choose appropriate antibiotics resulted in a 35% improvement in antibiotic selection for abdominal infections and a 28% improvement for skin/soft tissue infections.

The system uses patient-specific data from electronic medical records and hospital data to assess the risk of antibiotic-resistant infections. For low-risk patients, physicians were prompted to switch from broad-spectrum antibiotics to standard-spectrum alternatives. The research was based on pre-trial data from over 420,000 HCA Healthcare patients.

These INSPIRE trials address two of the four most common infections requiring hospitalization. HCA Healthcare is now implementing these protocols across its 190 hospitals, potentially improving care for millions of U.S. patients while helping combat the growing threat of antibiotic resistance.

HCA Healthcare (NYSE:HCA) has been recognized as a top performer on Fortune's 2025 World's Most Admired Companies list, ranking first in its industry. The recognition follows Fortune's analysis of 650 companies across 51 industries in 30 countries, evaluated on nine criteria including innovation, management quality, and financial soundness.

The healthcare provider, comprising approximately 316,000 colleagues, demonstrated significant community impact by deploying over 700 colleagues and contributing $1.5 million for hurricane relief during the 2024 Helene and Milton disasters. The company was also featured on Fortune's America's Most Innovative Companies list for its AI technologies and data-driven solutions implementation.

Notably, 33 HCA Healthcare hospitals were named on the 2025 Fortune/Premier 100 Top Hospitals list, spanning various categories including major teaching hospitals, teaching hospitals, and community hospitals of different sizes. The evaluation was based on clinical outcomes, operational efficiency, patient experience, and financial health metrics.

HCA Healthcare (NYSE: HCA) has scheduled its first quarter 2025 earnings conference call for Friday, April 25, 2025, at 9:00 AM Central Time (10:00 AM Eastern). The company will host a live audio webcast accessible through their investor relations website.

Investors and interested parties who cannot attend the live webcast can access the archived version of the call through HCA Healthcare's investor relations portal. For additional information, investors can contact Frank Morgan, Vice President of Investor Relations, while media inquiries should be directed to Harlow Sumerford.

HCA Healthcare (NYSE:HCA) has appointed Monica Cintado as senior vice president of development, succeeding Joseph A. Sowell who is retiring after more than 15 years of service. In her new role, Cintado will lead HCA Healthcare's enterprise development strategy, including mergers, acquisitions, divestitures, and strategic investments.

Cintado, who first joined HCA Healthcare in 1993, returned to the company in 2015 as vice president of development. She previously served as senior vice president of development at United Surgical Partners International. Her experience includes overseeing strategy, due diligence, negotiations, and regulatory approvals for acquisitions and divestitures.